(AFL) Aflac - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0010551028
Stock: Cancer, Medical, Accident, Life, Dental
Total Rating 44
Risk 78
Buy Signal 0.06
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.18% |
| Yield on Cost 5y | 7.11% |
| Yield CAGR 5y | 15.14% |
| Payout Consistency | 96.9% |
| Payout Ratio | 31.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 19.0% |
| Relative Tail Risk | -1.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | 2.40 |
| Character TTM | |
|---|---|
| Beta | 0.441 |
| Beta Downside | 0.548 |
| Drawdowns 3y | |
|---|---|
| Max DD | 13.56% |
| CAGR/Max DD | 1.60 |
Description: AFL Aflac January 29, 2026
Aflac Incorporated (NYSE:AFL) operates two distinct businesses-Aflic Japan, which sells a range of supplemental policies such as cancer, nursing-care and whole-life products, and Aflic U.S., which offers accident, disability, critical-illness, hospital-indemnity, dental, vision and life coverage. Distribution is diversified across independent agents, corporate agencies, banks and broker networks. The firm, founded in 1955 and headquartered in Columbus, Georgia, is classified under the Life & Health Insurance sub-industry.
Recent performance metrics highlight a 7.2% year-over-year increase in total earned premiums to $15.4 billion in 2025, driven largely by a 9.1% rise in the U.S. segment’s supplemental health line. The Japan segment contributed 22% of total premiums and posted a combined ratio of 94.3%, indicating underwriting profitability. Aflac’s earnings per share (EPS) for Q4 2025 came in at $2.18, surpassing consensus estimates by 6%, while its return on equity (ROE) held steady at 13.4% amid a rising interest-rate environment that is boosting investment income across the sector.
For a deeper quantitative dive into Aflac’s valuation drivers, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 3.65b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.52 > 1.0 |
| NWC/Revenue: 36.41% < 20% (prev 18.03%; Δ 18.38% < -1%) |
| CFO/TA 0.02 > 3% & CFO 2.57b > Net Income 3.65b |
| Net Debt (2.16b) to EBITDA (5.53b): 0.39 < 3 |
| Current Ratio: 5.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (532.0m) vs 12m ago -5.84% < -2% |
| Gross Margin: 38.65% > 18% (prev 0.41%; Δ 3824 % > 0.5%) |
| Asset Turnover: 14.84% > 50% (prev 16.27%; Δ -1.43% > 0%) |
| Interest Coverage Ratio: 21.0 > 6 (EBITDA TTM 5.53b / Interest Expense TTM 220.0m) |
Altman Z'' 2.83
| A: 0.05 (Total Current Assets 7.80b - Total Current Liabilities 1.48b) / Total Assets 116.47b |
| B: 0.47 (Retained Earnings 54.68b / Total Assets 116.47b) |
| C: 0.04 (EBIT TTM 4.62b / Avg Total Assets 117.02b) |
| D: 0.65 (Book Value of Equity 56.27b / Total Liabilities 86.98b) |
| Altman-Z'' Score: 2.83 = A |
Beneish M -2.90
| DSRI: 1.18 (Receivables 835.0m/779.0m, Revenue 17.36b/19.13b) |
| GMI: 1.06 (GM 38.65% / 40.85%) |
| AQI: 0.97 (AQ_t 0.93 / AQ_t-1 0.96) |
| SGI: 0.91 (Revenue 17.36b / 19.13b) |
| TATA: 0.01 (NI 3.65b - CFO 2.57b) / TA 116.47b) |
| Beneish M-Score: -2.90 (Cap -4..+1) = A |
What is the price of AFL shares?
As of February 09, 2026, the stock is trading at USD 117.15 with a total of 2,502,025 shares traded.
Over the past week, the price has changed by +4.64%, over one month by +6.25%, over three months by +3.68% and over the past year by +16.68%.
Over the past week, the price has changed by +4.64%, over one month by +6.25%, over three months by +3.68% and over the past year by +16.68%.
Is AFL a buy, sell or hold?
Aflac has received a consensus analysts rating of 3.08.
Therefor, it is recommend to hold AFL.
- StrongBuy: 1
- Buy: 2
- Hold: 8
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the AFL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 111.1 | -5.2% |
| Analysts Target Price | 111.1 | -5.2% |
| ValueRay Target Price | 142.7 | 21.8% |
AFL Fundamental Data Overview February 08, 2026
P/E Trailing = 17.1523
P/E Forward = 15.6006
P/S = 3.5773
P/B = 2.0661
P/EG = 0.93
Revenue TTM = 17.36b USD
EBIT TTM = 4.62b USD
EBITDA TTM = 5.53b USD
Long Term Debt = 8.41b USD (from longTermDebt, last quarter)
Short Term Debt = 399.0m USD (from shortTermDebt, two quarters ago)
Debt = 8.41b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.16b USD (from netDebt column, last quarter)
Enterprise Value = 63.56b USD (61.40b + Debt 8.41b - CCE 6.25b)
Interest Coverage Ratio = 21.0 (Ebit TTM 4.62b / Interest Expense TTM 220.0m)
EV/FCF = 24.70x (Enterprise Value 63.56b / FCF TTM 2.57b)
FCF Yield = 4.05% (FCF TTM 2.57b / Enterprise Value 63.56b)
FCF Margin = 14.82% (FCF TTM 2.57b / Revenue TTM 17.36b)
Net Margin = 21.00% (Net Income TTM 3.65b / Revenue TTM 17.36b)
Gross Margin = 38.65% ((Revenue TTM 17.36b - Cost of Revenue TTM 10.65b) / Revenue TTM)
Gross Margin QoQ = 59.91% (prev 43.90%)
Tobins Q-Ratio = 0.55 (Enterprise Value 63.56b / Total Assets 116.47b)
Interest Expense / Debt = 0.73% (Interest Expense 61.0m / Debt 8.41b)
Taxrate = 12.28% (193.0m / 1.57b)
NOPAT = 4.05b (EBIT 4.62b * (1 - 12.28%))
Current Ratio = 5.28 (Total Current Assets 7.80b / Total Current Liabilities 1.48b)
Debt / Equity = 0.29 (Debt 8.41b / totalStockholderEquity, last quarter 29.49b)
Debt / EBITDA = 0.39 (Net Debt 2.16b / EBITDA 5.53b)
Debt / FCF = 0.84 (Net Debt 2.16b / FCF TTM 2.57b)
Total Stockholder Equity = 27.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.12% (Net Income 3.65b / Total Assets 116.47b)
RoE = 13.05% (Net Income TTM 3.65b / Total Stockholder Equity 27.93b)
RoCE = 12.71% (EBIT 4.62b / Capital Employed (Equity 27.93b + L.T.Debt 8.41b))
RoIC = 11.33% (NOPAT 4.05b / Invested Capital 35.77b)
WACC = 6.71% (E(61.40b)/V(69.81b) * Re(7.54%) + D(8.41b)/V(69.81b) * Rd(0.73%) * (1-Tc(0.12)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.63%
[DCF Debug] Terminal Value 80.85% ; FCFF base≈2.83b ; Y1≈2.40b ; Y5≈1.82b
Fair Price DCF = 80.64 (EV 43.99b - Net Debt 2.16b = Equity 41.83b / Shares 518.7m; r=6.71% [WACC]; 5y FCF grow -18.49% → 2.90% )
EPS Correlation: 57.51 | EPS CAGR: 2.71% | SUE: -0.41 | # QB: 0
Revenue Correlation: -27.26 | Revenue CAGR: -1.95% | SUE: -0.26 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.80 | Chg30d=+0.001 | Revisions Net=-1 | Analysts=10
EPS current Year (2026-12-31): EPS=7.32 | Chg30d=-0.058 | Revisions Net=-4 | Growth EPS=-2.3% | Growth Revenue=-2.3%
EPS next Year (2027-12-31): EPS=7.75 | Chg30d=-0.104 | Revisions Net=-3 | Growth EPS=+6.0% | Growth Revenue=+3.3%
P/E Forward = 15.6006
P/S = 3.5773
P/B = 2.0661
P/EG = 0.93
Revenue TTM = 17.36b USD
EBIT TTM = 4.62b USD
EBITDA TTM = 5.53b USD
Long Term Debt = 8.41b USD (from longTermDebt, last quarter)
Short Term Debt = 399.0m USD (from shortTermDebt, two quarters ago)
Debt = 8.41b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.16b USD (from netDebt column, last quarter)
Enterprise Value = 63.56b USD (61.40b + Debt 8.41b - CCE 6.25b)
Interest Coverage Ratio = 21.0 (Ebit TTM 4.62b / Interest Expense TTM 220.0m)
EV/FCF = 24.70x (Enterprise Value 63.56b / FCF TTM 2.57b)
FCF Yield = 4.05% (FCF TTM 2.57b / Enterprise Value 63.56b)
FCF Margin = 14.82% (FCF TTM 2.57b / Revenue TTM 17.36b)
Net Margin = 21.00% (Net Income TTM 3.65b / Revenue TTM 17.36b)
Gross Margin = 38.65% ((Revenue TTM 17.36b - Cost of Revenue TTM 10.65b) / Revenue TTM)
Gross Margin QoQ = 59.91% (prev 43.90%)
Tobins Q-Ratio = 0.55 (Enterprise Value 63.56b / Total Assets 116.47b)
Interest Expense / Debt = 0.73% (Interest Expense 61.0m / Debt 8.41b)
Taxrate = 12.28% (193.0m / 1.57b)
NOPAT = 4.05b (EBIT 4.62b * (1 - 12.28%))
Current Ratio = 5.28 (Total Current Assets 7.80b / Total Current Liabilities 1.48b)
Debt / Equity = 0.29 (Debt 8.41b / totalStockholderEquity, last quarter 29.49b)
Debt / EBITDA = 0.39 (Net Debt 2.16b / EBITDA 5.53b)
Debt / FCF = 0.84 (Net Debt 2.16b / FCF TTM 2.57b)
Total Stockholder Equity = 27.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.12% (Net Income 3.65b / Total Assets 116.47b)
RoE = 13.05% (Net Income TTM 3.65b / Total Stockholder Equity 27.93b)
RoCE = 12.71% (EBIT 4.62b / Capital Employed (Equity 27.93b + L.T.Debt 8.41b))
RoIC = 11.33% (NOPAT 4.05b / Invested Capital 35.77b)
WACC = 6.71% (E(61.40b)/V(69.81b) * Re(7.54%) + D(8.41b)/V(69.81b) * Rd(0.73%) * (1-Tc(0.12)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.63%
[DCF Debug] Terminal Value 80.85% ; FCFF base≈2.83b ; Y1≈2.40b ; Y5≈1.82b
Fair Price DCF = 80.64 (EV 43.99b - Net Debt 2.16b = Equity 41.83b / Shares 518.7m; r=6.71% [WACC]; 5y FCF grow -18.49% → 2.90% )
EPS Correlation: 57.51 | EPS CAGR: 2.71% | SUE: -0.41 | # QB: 0
Revenue Correlation: -27.26 | Revenue CAGR: -1.95% | SUE: -0.26 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.80 | Chg30d=+0.001 | Revisions Net=-1 | Analysts=10
EPS current Year (2026-12-31): EPS=7.32 | Chg30d=-0.058 | Revisions Net=-4 | Growth EPS=-2.3% | Growth Revenue=-2.3%
EPS next Year (2027-12-31): EPS=7.75 | Chg30d=-0.104 | Revisions Net=-3 | Growth EPS=+6.0% | Growth Revenue=+3.3%